Synthesis and Characterization of NUC-7738, an Aryloxy Phosphoramidate of 3′-Deoxyadenosine, as a Potential Anticancer Agent

3 '-Deoxyadenosine (3 '-dA, Cordycepin, 1) is a nucleoside analogue with anticancer properties, but its clinical development has been hampered due to its deactivation by adenosine deaminase (ADA) and poor cellular uptake due to low expression of the human equilibrative transporter (hENT1). Here, we describe the synthesis and characterization of NUC-7738 (7a), a 5 '-aryloxy phosphoramidate prodrug of 3 '-dA. We show in vitro evidence that 7a is an effective anticancer drug in a panel of solid and hematological cancer cell lines, showing its preferential cytotoxic effects on leukemic stem cells. We found that unlike 3 '- dA, the activity of 7a was independent of hENT1 and kinase activity. Furthermore, it was resistant to ADA metabolic deactivation. Consistent with these findings, 7a showed increased levels of intracellular 3 '-deoxyadenosine triphosphate (3 '-dATP), the active metabolite. Mechanistically, levels of intracellular 3 '-dATP were strongly associated with in vitro potency. NUC-7738 is now in Phase II, dose-escalation study in patients with advanced solid tumors.

Automated summary

We report NUC-7738 (7a), a 5'-aryloxy phosphoramidate prodrug of 3'-deoxyadenosine, which showed effective anticancer activity against various cancer cell lines, particularly leukemic stem cells. Unlike 3'-dA, the activity of 7a was independent of cellular transporters and kinases, and it exhibited resistance to metabolic deactivation.